FDA Grants Fast Track Designation to SOTIO's SOT106 ADC for

The U.S. FDA granted Fast Track Designation to SOTIO's investigational antibody-drug conjugate SOT106 for treating soft tissue sarcoma, aiming to expedite its clinical development. SOT106 targets the LRRC15 protein prevalent in multiple sarcoma types and addresses significant unmet medical needs in this patient population.

This Wire brief sits within Fusion42's coverage of Biotech.